Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 in Pediatric H3 K27M Gliomas
NCT03416530Phase 1Terminated
- Sponsor
- Chimerix Inc.
- Start
- Jan 2018
- Primary completion
- Dec 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of dordaviprone in diffuse intrinsic pontine glioma (DIPG) and glioma, sponsored by Chimerix Inc. Primary endpoint: Recommended Phase 2 Dose at 28 days. Started Jan 2018; status: terminated.
02
Drugs
dordaviprone
03
Conditions
diffuse intrinsic pontine glioma (DIPG)glioma
Beyond the preview
Go deeper on NCT03416530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03416530.